Cochrane · systematic review · CD006687
Vasodilators for primary Raynaud's phenomenon
Su, KYC, Sharma, M, Kim, HJ, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
VascularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
42
current version
GRADE rated
19
No studies
16
Included studies
NR
No studies 16 · 38.1%Ungraded 7 · 16.7%Very low 8 · 19%Low 11 · 26.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Angiotensin‐converting enzyme inhibitors compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks (per week) (4 to 6‐week Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | 3 studies · 44 participants | Low Downgraded: risk of bias, inconsistency |
Severity of attacks (mild, moderate, and severe. then converted to numeric representation) (4 to 6‐week Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | 2 studies · 34 participants | Low Downgraded: risk of bias, imprecision |
Duration of attacks (minutes) (4 to 6‐week Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | 1 study · 14 participants | Low Downgraded: risk of bias, imprecision |
QoL Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
Adverse events (4 to 6‐week Angiotensin‐converting enzyme inhibitors vs placebo | RR 1.35 [0.67, 2.73] | 3 studies · 46 participants | Low Downgraded: risk of bias, inconsistency |
RCS Angiotensin‐converting enzyme inhibitors vs placebo | no estimate extracted | NR | No studies |
Alpha blockers compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks (4 weeks' to 180 days' Alpha blockers vs placebo | no estimate extracted | 1 study · 33 participants | Ungraded |
Severity of attacks (Dichotomous outcome over 4 weeks' to 180 days' Alpha blockers vs placebo | no estimate extracted | 1 study · 25 participants | Ungraded |
Duration of attacks (4 weeks) Alpha blockers vs placebo | no estimate extracted | 1 study · 33 participants | Ungraded |
QoL Alpha blockers vs placebo | no estimate extracted | NR | No studies |
Adverse events (4 weeks' to 180 days' Alpha blockers vs placebo | no estimate extracted | 1 study · 33 participants | Ungraded |
RCS Alpha blockers vs placebo | no estimate extracted | NR | No studies |
Prostagladin/prostacyclin analogues compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks per week (6 weeks' follow‐ up) Prostagladin/prostacyclin analogues vs placebo | no estimate extracted | 1 study · 118 participants | Low Downgraded: imprecision, inconsistency |
Severity of attacks (1 to 4 scale, 6 weeks' Prostagladin/prostacyclin analogues vs placebo | no estimate extracted | 1 study · 118 participants | Low Downgraded: imprecision, inconsistency |
Duration of attacks Prostagladin/prostacyclin analogues vs placebo | no estimate extracted | NR | No studies |
QoL Prostagladin/prostacyclin analogues vs placebo | no estimate extracted | NR | No studies |
Adverse events (6 weeks' Prostagladin/prostacyclin analogues vs placebo | RR 1.59 [1.05, 2.42] | 1 study · 125 participants | Low Downgraded: imprecision, inconsistency |
RCS Prostagladin/prostacyclin analogues vs placebo | no estimate extracted | NR | No studies |
Thromboxane synthase inhibitors compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks Per week (over 2 weeks) Thromboxane synthase inhibitors vs placebo | no estimate extracted | 1 study · 6 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Severity of attacks Thromboxane synthase inhibitors vs placebo | no estimate extracted | NR | No studies |
Duration of attacks Thromboxane synthase inhibitors vs placebo | no estimate extracted | NR | No studies |
QoL Thromboxane synthase inhibitors vs placebo | no estimate extracted | NR | No studies |
Adverse events Thromboxane synthase inhibitors vs placebo | no estimate extracted | NR | No studies |
RCS Thromboxane synthase inhibitors vs placebo | no estimate extracted | NR | No studies |
Selective serotonin reuptake inhibitors compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks Per week (over 4 weeks) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Severity of attacks (frequency of attacks/d × duration of attacks, over 4 weeks) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Duration of attacks Per day (minutes, over 4 weeks) Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
QoL Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | NR | No studies |
Adverse events (over 4 weeks) Selective serotonin reuptake inhibitors vs placebo | RR 1.54 [0.89, 2.66] | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
RCS Selective serotonin reuptake inhibitors vs placebo | no estimate extracted | NR | No studies |
Nitrate/nitrate derivatives compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks (1 or 4 weeks' Nitrate/nitrate derivatives vs placebo | no estimate extracted | 2 studies · 86 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Severity of attacks (1 week Nitrate/nitrate derivatives vs placebo | no estimate extracted | 1 study · 17 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Duration of attacks (2 or 4 weeks' Nitrate/nitrate derivatives vs placebo | no estimate extracted | 2 studies · 77 participants | Ungraded |
QoL Nitrate/nitrate derivatives vs placebo | no estimate extracted | NR | No studies |
Adverse events (3 weeks' Nitrate/nitrate derivatives vs placebo | no estimate extracted | 1 study · 8 participants | Ungraded |
RCS (4 weeks' Nitrate/nitrate derivatives vs placebo | no estimate extracted | 1 study · 69 participants | Low Downgraded: imprecision, inconsistency |
Phosphodiesterase inhibitors compared to placebo for primary Raynaud's phenomenon
Population: primary Raynaud's phenomenon
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of attacks (per week) (4 and 6 weeks' Phosphodiesterase inhibitors vs placebo | no estimate extracted | 2 studies · 111 participants | Low Downgraded: risk of bias, imprecision |
Severity of attacks (Likert scale 1 to 9 or 11 points; 4 and 6 weeks' Phosphodiesterase inhibitors vs placebo | no estimate extracted | 2 studies · 111 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Duration of attacks (4 weeks' Phosphodiesterase inhibitors vs placebo | no estimate extracted | 1 study · 73 participants | Low Downgraded: risk of bias, imprecision |
QoL Phosphodiesterase inhibitors vs placebo | no estimate extracted | NR | No studies |
Adverse events Phosphodiesterase inhibitors vs placebo | no estimate extracted | 3 studies · 138 participants | Ungraded |
RCS (6 weeks' Phosphodiesterase inhibitors vs placebo | no estimate extracted | 2 studies · 79 participants | Low Downgraded: risk of bias, imprecision |